Veracyte VCYT announces its next round of earnings this Monday, Feb. 25. Here's Benzinga's advanced look at Veracyte's Q4 earnings report.
Earnings and Revenue
Sell-side analysts are expecting Veracyte's loss per share to be near 15 cents on sales of $24.36 million.
In the same quarter last year, Veracyte announced an EPS loss of 24 cents on revenue of $19.5 million. Revenue would be up 24.31 percent from the year-ago period. In comparison to analyst estimates in the past, here's how the company's reported EPS stacks up:
| Quarter | Q3 2018 | Q2 2018 | Q1 2018 | Q4 2017 |
| EPS Estimate | -0.25 | -0.27 | -0.2 | |
| EPS Actual | -0.12 | -0.18 | -0.27 | -0.24 |
Stock Performance
Over the last 52-week period, shares are up 245.26 percent. Given that these returns are generally positive, long-term shareholders are probably happy going into this earnings release.
Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The most common rating by analysts on Veracyte stock is a Neutral. The strength of this rating has maintained conviction over the past three months.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
